

### **Redaction Log to Form HCMO-1 and Attachments**

*LucyRx OpCo, Inc. (“LucyRx”) respectfully requests highly confidential treatment under all applicable statutes, rules, and regulations. Without prejudice to the rights of LucyRx, if Oregon Health Authority or Department of Justice should at any time contemplate disclosing any such materials to the public or to any third party for any reason and for any use—including but not limited to quoting from, attaching, or otherwise referring to such documents in a court or administrative proceeding whether filed under seal or publicly—we request an opportunity of no fewer than three days advance notice to allow sufficient time to object and, if necessary, seek protections against disclosure from a court of competent jurisdiction.*

Document Description	Bates Range	Reason for Redaction	Grounds for Exemption
Exhibit 7a: Stock Purchase Agreement – Project Lotus	HCMO_LUCYRX_0000007-92 HCMO_LUCYRX_0001191-1450	The Parties request confidential treatment of the Stock Purchase Agreement and its exhibits. The Stock Purchase Agreement contains confidential business terms, strategic rationale, and proprietary information related to the proposed transaction that has not been made publicly available in any other forum. Information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the company's operating model. Disclosure of this document could result in competitive harm and it includes material protected under Oregon Law.	ORS 415.501(13)(c); ORS 192.345(2); ORS 192.355(9)(a); ORS 646.461 et seq.
Exhibit 7b: Project Lotus – HSR Filing	HCMO_LUCYRX_0000334-1190	LucyRx requests confidential treatment of its filing under the Hart-Scott-Rodino Antitrust Improvements Act (“HSR Filing”). The HSR Filing contains sensitive commercial and financial information submitted pursuant to federal premerger notification requirements. This includes strategic transaction details, valuation data, and proprietary business plans that are customarily kept private and not disclosed to the public. Disclosure could result in competitive harm and undermine the integrity of the transaction process. Accordingly, this information qualifies as confidential under Exemption 4 of the Freedom of Information Act (FOIA), as well as under Oregon Law.	5 U.S.C. § 552(b)(4); ORS 415.501(13)(c); ORS 192.345(2); ORS 192.355(9)(a); ORS 646.461 et seq.

Document Description	Bates Range	Reason for Redaction	Grounds for Exemption
Exhibit 7b: Project Lotus Diligence Reports	HCMO_LUCYRX_0001451-1566	LucyRx requests confidential treatment of: (1) Aon's Risk & Insurance Due Diligence Report; (2) Brown & Brown's Employee Benefits Due Diligence Report; (3) PHSL's Pharmacy Solutions Due Diligence Report; (4) PwC's Financial Due Diligence Report; and (5) PwC's Tax Observations (collectively "the Diligence Reports"). The Diligence Reports contain proprietary analyses prepared by third-party consultants to inform the transaction. These reports include non-public evaluations of liability exposure, benefit structures, vendor relationships, pricing methodologies, financial performance, and tax. The contents reflect strategic planning and internal decision-making processes that are customarily kept confidential and shared only under strict nondisclosure agreements. Disclosure would provide competitors with insight into the company's risk posture, compensation philosophy, pharmacy operations, and financial condition, resulting in potential economic harm. These materials qualify as trade secrets under ORS 192.345(2) due to their economic value, the confidentiality measures in place, and the substantial effort and expense required to compile them.	ORS 415.501(13)(c); ORS 192.345(2); ORS 192.355(9)(a); ORS 646.461 et seq.
Exhibit 10b: LucyRx Governance Documents	HCMO_LUCYRX_0000093-263	LucyRx requests confidential treatment of its non-public Governance Documents. The Governance Documents contain confidential information that is not publicly available and that is obtained in relation to a material change transaction. The Governance Documents contain internal operational protocols, decision-making structures, and proprietary organizational frameworks specific to a non-public entity. Disclosure of these materials could expose sensitive business practices and strategic governance models, potentially resulting in competitive harm. These documents are not publicly available and are protected under Oregon Law as confidential business information.	ORS 415.501(13)(c); ORS 192.345(2); ORS 192.355(9)(a); ORS 646.461 et seq.

Document Description	Bates Range	Reason for Redaction	Grounds for Exemption
Exhibit 10c: LucyRx Pre-Closing Structure Chart	HCMO_LUCYRX_0000264-265	LucyRx requests confidential treatment of the Pre-Closing Structure Chart. The Pre-Closing Structure chart reflects LucyRx's internal ownership and control structure, including the strategic deployment of intermediary legal entities designed to manage risk and support operational flexibility. This configuration is not publicly disclosed and is the result of significant legal and financial planning. LucyRx has taken deliberate steps to keep this structure confidential, including limiting internal access and requiring nondisclosure agreements from external advisors. Disclosure would reveal proprietary structuring strategies that competitors could replicate or exploit, causing economic harm. The chart qualifies as a trade secret under ORS 192.345(2) due to its economic value, confidentiality protections, and the substantial effort required to develop and maintain it.	ORS 415.501(13)(c); ORS 192.345(2); ORS 192.355(9)(a); ORS 646.461 et seq.
Exhibit 10e: LucyRx Financial Statements FY 22-24	HCMO_LUCYRX_0000266-331	LucyRx requests confidential treatment of its Financial Statements. The Financial Statements contain confidential information and documents that are not publicly available and that are provided in relation to a material change transaction. The Financial Statements include non-public financial data, performance metrics, and projections that reflect the internal financial condition and strategic positioning of the entity. Public disclosure could compromise competitive standing and reveal trade secrets, and is therefore protected under Oregon Law.	ORS 415.501(13)(c); ORS 192.345(2); ORS 192.355(9)(a); ORS 646.461 et seq.

<b>Document Description</b>	<b>Bates Range</b>	<b>Reason for Redaction</b>	<b>Grounds for Exemption</b>
Exhibit 13a: LucyRx Post-Closing Structure Chart	HCMO_LUCYRX_0000332-333	LucyRx requests confidential treatment of the Post-Closing Structure Chart. The Post-Closing Structure chart outlines LucyRx's anticipated ownership and governance structure following the transaction, including the planned deployment of holding companies and intermediary entities to support integration and future growth. This forward-looking structure reflects confidential strategic planning and is not publicly available. LucyRx has safeguarded this information internally and through contractual confidentiality with external parties. Public disclosure would expose sensitive business strategies and allow competitors to anticipate or counter LucyRx's market positioning. The chart constitutes a trade secret under ORS 192.345(2) due to its confidential nature, economic value, and the time and resources invested in its development.. This information is exempt from public disclosure under Oregon Law.	ORS 415.501(13)(c); ORS 192.345(2); ORS 192.355(9)(a); ORS 646.461 et seq.
Appendix to HCMO-1	HCMO_LUCYRX_0000000	The Parties request confidential treatment of certain disclosures made in the Notice of Material Change Transaction, included in Appendix to HCMO-1. Certain responses in the Appendix to HCMO-1 contain confidential business information, including strategic rationale, financial assumptions, and proprietary methodologies. Disclosure of these responses could undermine competitive positioning and reveal trade secrets, and is therefore protected under Oregon Law.	ORS 415.501(13)(c); ORS 192.345(2); ORS 192.355(9)(a); ORS 646.461 et seq.

**LucyRx OpCo, Inc. reserves the right to amend or supplement this log.**